Allogene Therapeutics (ALLO) Receivables - Net (2020)

Allogene Therapeutics (ALLO) reported Receivables - Net of $3.1 million for Q3 2020, up 287.5% sequentially from $800000.0 in Q2 2020.

Allogene Therapeutics (ALLO) Receivables - Net (2020) Analysis & Trends

Allogene Therapeutics (ALLO) has 1 years of Receivables - Net data on file, last reported at $3.1 million in Q3 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Allogene Therapeutics 437.33 Mn 437.33 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2020 3.10 Mn
Sep 30, 2020 3.10 Mn
Jun 30, 2020 800,000.00
Jun 30, 2020 800,000.00
Mar 31, 2020 200,000.00
Mar 31, 2020 200,000.00